In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Developing enhanced digital content to increase physician engagement
With in-person scientific congresses an impossibility for the foreseeable future, researchers and publishers have to adapt how they foster scientific exchange. Experts from ICON's Medical Communications team discuss how they are using enhanced media fit for the digital age.
-
-
Right, left and centre
An article featuring expert commentary from ICON's Gretchen Goller on the importance of including patients at every stage of drug development.
-
Innovation in oncology drug development: A focus on patient benefits
An article by ICON's Dr. Brian Huber that examines how innovation, from the development of targeted therapies to a revolution in clinical trial designs, puts an emphasis on patient centricity.
-
Decentralised and hybrid trials – the patient’s voice
A thought leadership article by ICON's Gretchen Goller on getting the patient perspective on clinical trial participation.
-
A pathway to recovery
An opinion article from ICON's Chief Medical Officer, Kristen Buck on the role of Chief Medical Officers.
-
Treatment options for Clostridioides difficile
This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. Samedan Ltd.
-
An outsourced model for pharmacovigilance at an affiliate level
A thought leadership article on pharmacovigilance, written by Barry Rice and Sharlene Ahmed centered around improving oversight and reducing the risk of non-compliance.
-
A golden opportunity… but not a silver bullet
This spotlight feature authored by ICON's Barry Balfe examines how pharmaceutical companies are increasing their functional service partnership expenditure at a rapid rate, and the key considerations in selecting and executing the FSP model which are being overlooked.
-
Decentralised trials – aided by tech – could boost clinical research
A Pharmaphorum article which considers how bringing clinical trials to patients – rather than the reverse – could be the key to improving recruitment into studies and making them faster, cheaper and more likely to succeed.
